YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

Informe acción SEHK:1558

Capitalización de mercado: HK$8.0b

YiChang HEC ChangJiang Pharmaceutical Dirección

Dirección controles de criterios 3/4

El CEO de YiChang HEC ChangJiang Pharmaceutical es Juncai Jiang , nombrado en May 2015, tiene una permanencia de 9.5 años. compensación anual total es CN¥2.57M, compuesta por 18.7% salario y 81.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.008% de las acciones de la empresa, por valor de HK$609.12K. La antigüedad media del equipo directivo y de la junta directiva es de 7.3 años y 7.3 años, respectivamente.

Información clave

Juncai Jiang

Chief Executive Officer (CEO)

CN¥2.6m

Compensación total

Porcentaje del salario del CEO18.7%
Permanencia del CEO9.5yrs
Participación del CEO0.008%
Permanencia media de la dirección7.3yrs
Promedio de permanencia en la Junta Directiva7.3yrs

Actualizaciones recientes de la dirección

Recent updates

YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Strong Profits May Be Masking Some Underlying Issues

Oct 07
YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Strong Profits May Be Masking Some Underlying Issues

Should You Be Adding YiChang HEC ChangJiang Pharmaceutical (HKG:1558) To Your Watchlist Today?

Sep 19
Should You Be Adding YiChang HEC ChangJiang Pharmaceutical (HKG:1558) To Your Watchlist Today?

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Popularity With Investors Under Threat As Stock Sinks 26%

May 29
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Popularity With Investors Under Threat As Stock Sinks 26%

Do YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings Warrant Your Attention?

Apr 23
Do YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings Warrant Your Attention?

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) P/S Is Still On The Mark Following 33% Share Price Bounce

Mar 01
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) P/S Is Still On The Mark Following 33% Share Price Bounce

Investors Appear Satisfied With YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Prospects As Shares Rocket 33%

Mar 01
Investors Appear Satisfied With YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Prospects As Shares Rocket 33%

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Business Is Trailing The Industry But Its Shares Aren't

Jan 03
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Business Is Trailing The Industry But Its Shares Aren't

YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt

Sep 25
YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt

Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?

Nov 25
Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?

Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?

Mar 23
Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?

Does This Valuation Of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Imply Investors Are Overpaying?

Oct 29
Does This Valuation Of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Imply Investors Are Overpaying?

Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden

Apr 13
Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Analysts Just Cut Their EPS Forecasts Substantially

Mar 23
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Analysts Just Cut Their EPS Forecasts Substantially

YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Share Price Is Down 55% Over The Past Three Years.

Mar 13
YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Share Price Is Down 55% Over The Past Three Years.

YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Is Growing Earnings But Are They A Good Guide?

Feb 20
YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Is Growing Earnings But Are They A Good Guide?

Do Institutions Own YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Shares?

Feb 02
Do Institutions Own YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Shares?

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Dec 26
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Key Things To Watch Out For If You Are After YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) 5.1% Dividend

Dec 13
Key Things To Watch Out For If You Are After YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) 5.1% Dividend

What Type Of Returns Would YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Nov 30
What Type Of Returns Would YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Juncai Jiang en comparación con los beneficios de YiChang HEC ChangJiang Pharmaceutical?
FechaCompensación totalSalarioIngresos de la empresa
Jun 30 2024n/an/a

CN¥2b

Mar 31 2024n/an/a

CN¥2b

Dec 31 2023CN¥3mCN¥482k

CN¥2b

Sep 30 2023n/an/a

CN¥2b

Jun 30 2023n/an/a

CN¥1b

Mar 31 2023n/an/a

CN¥608m

Dec 31 2022CN¥1mCN¥600k

CN¥77m

Sep 30 2022n/an/a

-CN¥18m

Jun 30 2022n/an/a

-CN¥113m

Mar 31 2022n/an/a

-CN¥351m

Dec 31 2021CN¥1mCN¥490k

-CN¥588m

Sep 30 2021n/an/a

-CN¥436m

Jun 30 2021n/an/a

-CN¥285m

Mar 31 2021n/an/a

CN¥277m

Dec 31 2020CN¥756kCN¥229k

CN¥839m

Sep 30 2020n/an/a

CN¥1b

Jun 30 2020n/an/a

CN¥2b

Mar 31 2020n/an/a

CN¥2b

Dec 31 2019CN¥393kCN¥222k

CN¥2b

Sep 30 2019n/an/a

CN¥2b

Jun 30 2019n/an/a

CN¥1b

Mar 31 2019n/an/a

CN¥1b

Dec 31 2018CN¥365kCN¥209k

CN¥943m

Sep 30 2018n/an/a

CN¥961m

Jun 30 2018n/an/a

CN¥980m

Mar 31 2018n/an/a

CN¥813m

Dec 31 2017CN¥324kCN¥194k

CN¥647m

Compensación vs. Mercado: La compensación total ($USD355.29K) de Juncai está en línea con el promedio de empresas de tamaño similar en el mercado Hong Kong ($USD466.36K).

Compensación vs. Ingresos: La compensación de Juncai ha aumentado más de un 20% en el último año.


CEO

Juncai Jiang (42 yo)

9.5yrs

Permanencia

CN¥2,572,000

Compensación

Mr. Juncai Jiang has been General Manager and Executive Director of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. since joining in May 2015. Mr. Jiang served as Deputy Head of the traditional Chinese med...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Juncai Jiang
GM & Executive Director9.5yrsCN¥2.57m0.0076%
HK$ 609.1k
Yangui Chen
Head of the Sales Department10.5yrsCN¥645.00ksin datos
Danjin Wang
Deputy GM & Executive Director9.5yrsCN¥2.71m0.0076%
HK$ 613.1k
Shuang Li
Deputy GM & Executive Director9.5yrsCN¥1.32m0.0076%
HK$ 609.1k
Hao Chen
Executive Director1.2yrsCN¥1.59msin datos
Qiang Zhang
CFO & Head of Finance Department5.8yrsCN¥480.38ksin datos
Shengchao Wang
Chief of Quality Division & Employee Representative Supervisor7.3yrssin datos0.0036%
HK$ 292.1k
Qiyun Peng
Joint Company Secretary6.1yrsCN¥370.31ksin datos
Wai Chiu Wong
Joint Company Secretary2.8yrssin datossin datos

7.3yrs

Permanencia media

43yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 1558 es experimentado (7.3 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Juncai Jiang
GM & Executive Director9.5yrsCN¥2.57m0.0076%
HK$ 609.1k
Danjin Wang
Deputy GM & Executive Director18.8yrsCN¥2.71m0.0076%
HK$ 613.1k
Shuang Li
Deputy GM & Executive Director6.4yrsCN¥1.32m0.0076%
HK$ 609.1k
Hao Chen
Executive Director1.2yrsCN¥1.59msin datos
Shengchao Wang
Chief of Quality Division & Employee Representative Supervisor7.3yrssin datos0.0036%
HK$ 292.1k
Xinfa Tang
Non-Executive Chairman9.5yrsCN¥32.19m0.015%
HK$ 1.2m
Jianxin Tang
Independent Non-Executive Director9.5yrsCN¥100.00ksin datos
Zhonghua Luo
Supervisor7.4yrssin datos0.0076%
HK$ 609.1k
Jinlong Tang
Chairman of the Board of Supervisors5.4yrssin datossin datos
Ling Xiang
Independent Non Executive Director4.4yrsCN¥100.00ksin datos
Xuechen Li
Independent Non-Executive Director4.2yrsCN¥340.00k0.00045%
HK$ 36.1k

7.3yrs

Permanencia media

46yo

Promedio de edad

Junta con experiencia: La junta directiva de 1558 se considera experimentada (7.3 años de antigüedad promedio).